welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Muscle MRI in Becker Muscular Dystrophy and in Limb-girdle Muscular Dystrophy Type 2I
study id #: NCT02165358
condition: Becker Muscular Dystrophy, Limb-Girdle Muscular Dystrophy Type 2I
The purpose of this study is to investigate the paradoxical muscle enlargement in the calves and tongue seen in patients affected by Becker muscular dystrophy and Limb-girdle muscular dystrophy type 2I. The enlarged calves’ muscle quality will be assessed primarily on the basis of the muscle structure on MRI and based on a calculation of muscle strength per cross-sectional area.The findings will be compared with results from non-affected controls. Additionally we want to describe the tongue muscle appearance on T1-weighted MRI.
mechanism of action: No pharmaceutical intervention
last updated: November 21, 2018
start date: June 2014
estimated completion: January 2015
size / enrollment: 38
The purpose of this study is to investigate the paradoxical muscle enlargement seen in patients affected by Becker muscular dystrophy and Limb-girdle muscular dystrophy type 2I.
Becker and limb-girdle muscular dystrophies are both hereditary muscular disorders. Both diseases appear clinically with shrinkage and muscle weakness of the muscles around the shoulder girdle and pelvis, while muscle hypertrophy of the calves and tongue is seen.
The quality of the enlarged calves has to the investigators knowledge not previously been described, and their hypothesis is that the normal correlation between muscle strength and muscle cross-section is absent in the calf muscles. Thus the investigators hypothesis suggests that there is no actual hypertrophy of the calf muscles, but rather a pseudohypertrofy with reduced force per cross-sectional area. With a picture of increased fat infiltration and disorganized muscle fibers.
The enlarged calves' muscle quality will be assessed primarily on the basis of the muscle structure on MRI (assessed on both T1 imaging, 3-point Dixon scans, and diffusion tension imaging), and based on a calculation of muscle strength per cross-sectional area. Isokinetic muscle dynamometry (Biodex-4) will be used to measure muscle strength. The findings will be compared with results from non-affected controls.
Additionally the investigators want to describe the tongue muscle appearance on T1-weighted MRI.
- Calves muscle quality [ Time Frame: 1 day ]
The investigators will describe muscle quality by:
• MRI scans of the calves comprising of a T1-weighted MRI scan, a 3-point Dixon scan to measure the fraction of fat in the muscle, a short TI inversion recovery (STIR) scan, and a diffusion tensor imaging (DTI) scan to see the muscle fiber organization.
The MRI scans will further be used to measure the fat free muscle cross-sectional area of the muscle groups responsible for plantar flexion and dorsi flexion respectively.
• Biodex muscle strength measurements: Isokinetic muscle dynamometry measurements on plantar flexion and dorsal flexion over the ankle.
• Calculating of muscle strength per muscle cross-sectional area
- MRI T1 scan of the tongue [ Time Frame: 1 day ]
MRI T1 scan of the tongue to investigate muscle volume
Danish patients genetically verified with either becker muscular dystrophy or limb-girdle muscular dystrophy type 2I
• Patients who have metal implants in the body, for instance surgical clips, cochlear implants, pacemaker etc.
• pregnant or breast-feeding patients
• patients who are claustrophobic
• atrophic calves
Phase 1/2 Study in Boys With Duchenne Muscular DystrophyThe MoveDMD study is a 3-part, Phase 1/2...
Tadalafil in Becker Muscular DystrophySummary for Patients: This study, funded...
(-)- Epicatechin Becker Muscular DystrophyThis is a 48-week open-label extension o...
Safety Study of Flavocoxid in Duchenne Muscular DystrophyObjective of this study is to evaluate s...
Extension Study of ACE-031 in Subjects With Duchenne Muscular DystrophyTo evaluate the long-term safety and tol...
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation DystrophinopathyThe primary objective of this study is t...
Design of a phase 3 trial to evaluate the long-term efficacy and safety of ataluren in patients with nonsense mutati...Ataluren is conditionally approved by th...
Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystr...Sarepta Therapeutics, Inc., a commercial...
The Treatment of Duchenne Muscular Dystrophy: Equipoise, Fidelity and Standardshttps://www.youtube.com/watch?v=ji7Z23qH...
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrop...Catabasis Pharmaceuticals, Inc., a clini...
State-of-the-art advances in Duchenne muscular dystrophyDuchenne muscular dystrophy (DMD) is a s...